PE20040777A1 - Proceso para la preparacion de (s,s)-cis-2-benzhidril-3-bencilaminoquinuclidina - Google Patents

Proceso para la preparacion de (s,s)-cis-2-benzhidril-3-bencilaminoquinuclidina

Info

Publication number
PE20040777A1
PE20040777A1 PE2003001050A PE2003001050A PE20040777A1 PE 20040777 A1 PE20040777 A1 PE 20040777A1 PE 2003001050 A PE2003001050 A PE 2003001050A PE 2003001050 A PE2003001050 A PE 2003001050A PE 20040777 A1 PE20040777 A1 PE 20040777A1
Authority
PE
Peru
Prior art keywords
acid
acid salt
isomer
chiral
benzylaminoquinuclidina
Prior art date
Application number
PE2003001050A
Other languages
English (en)
Spanish (es)
Inventor
Thomas C Nugent
Jack Liang
Robert Seemayer
Original Assignee
Pfizer Prod Inc
Dsm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Dsm Pharmaceuticals Inc filed Critical Pfizer Prod Inc
Publication of PE20040777A1 publication Critical patent/PE20040777A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2003001050A 2002-10-16 2003-10-14 Proceso para la preparacion de (s,s)-cis-2-benzhidril-3-bencilaminoquinuclidina PE20040777A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41905102P 2002-10-16 2002-10-16

Publications (1)

Publication Number Publication Date
PE20040777A1 true PE20040777A1 (es) 2004-11-20

Family

ID=32108014

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001050A PE20040777A1 (es) 2002-10-16 2003-10-14 Proceso para la preparacion de (s,s)-cis-2-benzhidril-3-bencilaminoquinuclidina

Country Status (21)

Country Link
US (2) US6861526B2 (enExample)
EP (1) EP1551833A4 (enExample)
JP (1) JP2006506368A (enExample)
KR (1) KR100739901B1 (enExample)
CN (1) CN100418964C (enExample)
AP (1) AP2005003288A0 (enExample)
AR (1) AR041587A1 (enExample)
AU (1) AU2003277353B2 (enExample)
BR (1) BR0315335A (enExample)
CA (1) CA2500635A1 (enExample)
EA (1) EA008192B1 (enExample)
HR (1) HRP20050328A2 (enExample)
IS (1) IS7755A (enExample)
MX (1) MXPA05004058A (enExample)
PA (1) PA8586601A1 (enExample)
PE (1) PE20040777A1 (enExample)
PL (1) PL376218A1 (enExample)
TN (1) TNSN05111A1 (enExample)
UY (1) UY28024A1 (enExample)
WO (1) WO2004035575A1 (enExample)
ZA (1) ZA200502411B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
NZ548236A (en) * 2004-01-30 2010-02-26 Pfizer Prod Inc Compositions comprising (2S.3S) (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-alkyl-2-methoxy-benzyl)-amine derivatives
AU2005210259A1 (en) * 2004-02-02 2005-08-18 Pfizer Products Inc. Process for preparation of 1-(2S,3S)-2-benzhydr yl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法
CN108341811A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 马罗皮坦杂质的制备方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
WO1990005525A1 (en) 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5138060A (en) 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
DE69232334T2 (de) 1991-05-22 2002-11-14 Pfizer Inc., New York Substituierte 3-aminochinuclidine
SK278788B6 (sk) * 1991-05-31 1998-02-04 Pfizer Inc. Chinuklidínové deriváty, spôsob ich prípravy a pou
EP1114823A3 (en) 1992-08-19 2001-07-18 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
DK0668863T3 (da) * 1992-11-12 1997-06-30 Pfizer Quinuclidinderivat som substans P-antagonist
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
MX9706944A (es) 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.

Also Published As

Publication number Publication date
IS7755A (is) 2005-03-17
EA008192B1 (ru) 2007-04-27
UY28024A1 (es) 2004-05-31
KR100739901B1 (ko) 2007-07-13
CN100418964C (zh) 2008-09-17
US20050085641A1 (en) 2005-04-21
AU2003277353A1 (en) 2004-05-04
US6861526B2 (en) 2005-03-01
EP1551833A1 (en) 2005-07-13
HRP20050328A2 (en) 2005-06-30
PL376218A1 (en) 2005-12-27
WO2004035575A8 (en) 2005-05-12
TNSN05111A1 (en) 2007-05-14
KR20050083764A (ko) 2005-08-26
AP2005003288A0 (en) 2005-06-30
BR0315335A (pt) 2005-08-16
AU2003277353B2 (en) 2007-08-09
MXPA05004058A (es) 2005-06-08
JP2006506368A (ja) 2006-02-23
EA200500650A1 (ru) 2005-10-27
US20040116704A1 (en) 2004-06-17
EP1551833A4 (en) 2010-06-02
CA2500635A1 (en) 2004-04-29
PA8586601A1 (es) 2005-02-04
AR041587A1 (es) 2005-05-26
HK1078087A1 (en) 2006-03-03
WO2004035575A1 (en) 2004-04-29
ZA200502411B (en) 2006-05-31
CN1705664A (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
PE20040777A1 (es) Proceso para la preparacion de (s,s)-cis-2-benzhidril-3-bencilaminoquinuclidina
KR100990949B1 (ko) 클로피도그렐 및 그의 유도체의 제조방법
EA200200511A1 (ru) Соли производных 3,3-дифенилпропиламинов
RU2627698C2 (ru) Натриевая соль (2s, 5r)-6-бензилокси-7-оксо-1,6-диаза-бицикло[3.2.1]октан-2-карбоновой кислоты и ее получение
BR0316902A (pt) Processos para preparar (+)duloxetina e hidrocloreto de (+)duloxetina, sal de ácido quiral e (+)duloxetina, di-p-toluil tartarato de (+)duloxetina, (+)duloxetina e composição farmacêutica
AR059296A1 (es) Compuesto de l-tartrato de s-zopiclona y proceso para resolver los enantiomeros de zopiclona.
WO2019077332A1 (en) THERAPEUTIC COMPOUNDS
EA200400129A1 (ru) Способ получения периндоприла, его аналогов и солей с использованием 2,5-диоксооксазолидиновых промежуточных соединений
MX2010001229A (es) Procedimiento para la resolucion de zopiclona y compuestos intermedios.
EA201170057A1 (ru) Способ получения замещенных 2-аминотиазолонов
ATE441627T1 (de) Verfahren zur herstellung von valsartan
DE60110970T2 (de) Herstellung von gemischten Säureanhydriden und Amidverbindungen
KR101561828B1 (ko) α-아미노산의 라세미화 방법
KR101430116B1 (ko) 스트레커 반응용 촉매를 사용하는 키랄성 α-아미노나이트릴의 제조방법
ES2827454T3 (es) Método para preparar un compuesto intermedio de citalopram diol
ES2894975T3 (es) Proceso para la preparación de clorhidrato de isoproterenol
DE69108553T2 (de) Inhibitoren fur angiotensin umwandelnde enzyme.
KR101498802B1 (ko) 키랄 2-아미노-4h-크로멘 유도체의 제조방법
DE602006008335D1 (de) Neuartiges verfahren zur herstellung von quaternärer säure und ammoniumsalzen
AR126158A1 (es) Proceso de una sola etapa para la preparación de un aminoácido quiral
RU2004124844A (ru) Прукалоприд-n-оксид
JPWO2021172204A5 (enExample)
KR20060060020A (ko) 1-카바모일사이클로알킬카복실산 화합물, 이의 제조방법 및이의 용도
KR101453413B1 (ko) 알파-카르볼린 유도체의 제조방법
US20050079589A1 (en) Process for preparing R- and S-isomers of (R)-5-(2-( (2-(2-ethoxyphenoxy) ethyl) amino) propyl) -2-methoxybenzenesulfonamide

Legal Events

Date Code Title Description
FA Abandonment or withdrawal